CBC Group
VC Fund
CBC Group is a healthcare-dedicated investment firm that creates value and integrates global resources.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries CBC Group invests in
Stages CBC Group invests in
Countries CBC Group invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Kerry Blanchard
|
|||
|
Ma Ke
|
|||
Sean Cao
|
|||
1 more contact available
Investment Focus
Industry
- Biotechnology 6 (60%)
- Health Care 4 (40%)
- Biopharma 3 (30%)
- Pharmaceutical 3 (30%)
- Life Science 2 (20%)
Stage
- Series B 4 (40%)
- Pre-Seed 2 (20%)
- Post-IPO Debt 2 (20%)
- Angel 1 (10%)
- Series A 1 (10%)
Country
- China 4 (40%)
- United States 4 (40%)
- Japan 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Kerry Blanchard
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
Lincoln Chee Wang Jin
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Ma Ke
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
|
Sean Cao
Managing Director
|
Managing Director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Hailong Aerospace
|
Hailong Aerospace is a technological business that specializes in system solutions and high-precision attitude control components for commercial satellites. Hailong Aerospace specializes in high-precision satellite attitude control systems, specifically the "steering wheel" and "stabilizer" of commercial aircraft. | Angel / Jul 09, 2026 | |
Hunan Yiyi Pharmaceutical Technology
|
Hunan Yiyi Pharmaceutical Technology | Series B / Aug 31, 2022 | |
Sironax
|
Sironax is a pharmaceuticals company for inflammatory and neuro-degenerative diseases. | $200M / Series B / Aug 02, 2022 | |
Axbio
|
Axbio manufactures next-generation gene sequencing and diagnostic high-end equipment and providing complete industrial solutions. | $100M / Series B / Jun 20, 2022 | |
InxMed
|
InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equippedwith global-level top-notch know-how and efficient execution capabilities. | $15M / Series B / May 08, 2022 | |
ENSEM Therapeutics
|
ENSEM Therapeutics is a pioneering drug discovery and development company that leverages its unique Kinetic EnsembleTM platform to develop innovative small-molecule precision medicines for oncology, with potential expansion into genetic disorders and other disease areas. | $67M / Series A / Apr 06, 2022 | |
Trevena
|
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines.They have three programs in development:TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas. | $40M / Post-IPO Debt / Mar 31, 2022 | |
Paratek Pharmaceuticals
|
Paratek Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet andintravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI), and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received the Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP. | $60M / Post-IPO Debt / Jan 04, 2021 | |
Jadeite Medicines
|
Jadeite Medicines is a biopharmaceutical platform that develops pharmaceutical products. | Pre-Seed / Jan 01, 2021 | |
ABio-X
|
ABIO-X incubates organizations at the intersection of ground-breaking technologies and cutting-edge science with the goal of bringing transformative medicines and solutions to the global market. Each company will have its own product portfolio and operations, which will be controlled by its own leadership team and backed by a centralized sharedservices environment. | Pre-Seed / Jan 01, 2021 |
Co-Investors
GGV Capital
3 deals together
Cenova
2 deals together
YF Capital
2 deals together
ABio-X
1 deal together
ARCH Venture Partners
1 deal together
AstraZeneca Pharmaceutical
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does CBC Group invest in?
CBC Group invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series B and Pre-Seed stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CBC Group?
Public channels for CBC Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CBC Group?
The team at CBC Group includes Kerry Blanchard (Operating Partner), Lincoln Chee Wang Jin (Managing Director) and Ma Ke (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
